How to Test for Predicting Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer? Evidence From the Secondary Analysis of Biomarkers of CALGB/SWOG 80405.
Andrea Sartore-Bianchi, Silvia Marsoni, Alessio Amatu, Valter Torri, Emanuela Bonoldi, Alberto Bardelli, Livio Trusolino, Salvatore Siena
Author Information
- Andrea Sartore-Bianchi: Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, "Mario Negri" Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy. ORCID
- Silvia Marsoni: Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, "Mario Negri" Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy. ORCID
- Alessio Amatu: Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, "Mario Negri" Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy. ORCID
- Valter Torri: Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, "Mario Negri" Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy. ORCID
- Emanuela Bonoldi: Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, "Mario Negri" Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy.
- Alberto Bardelli: Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, "Mario Negri" Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy. ORCID
- Livio Trusolino: Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, "Mario Negri" Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy. ORCID
- Salvatore Siena: Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, "Mario Negri" Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Universit�� degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Universit�� degli Studi di Milano, Milan, Italy. ORCID
No abstract text available.
